Bristol Myers Squibb (BMS) announced the appointment of Cristian Massacesi, formerly chief medical officer at AstraZeneca and Alexion, as its new CMO effective August 1. Massacesi replaces outgoing Samit Hirawat, who led BMS’s notable oncology drug launches including Reblozyl and Opdualag. Massacesi's extensive oncology and rare disease development experience, including prior roles at Pfizer and Novartis, is expected to aid BMS as it navigates patent expirations and generic competition challenges in key drug franchises.